Recombinant Mouse IL-2 (carrier-free)

Product Details

Source

Mouse IL-2, amino acids Ala21-Gln169 (Accession # NM_008366) was expressed in E. coli.

Molecular Mass

The 150 amino acid N-terminal methionylated recombinant protein has a predicted molecular mass of 17,231 Da. The DTT-reduced protein and non-reduced protein migrates at approximately 18kDa by SDS-PAGE.

Purity

Purity is >98%, as determined by Coomassie stained SDS-PAGE.

Formulation

0.22 µm filtered protein solution is in 5 mM NaH2PO4, 5 mM citric acid, 350 mM NaCl, 1 mM TCEP, pH 4.0.

Endotoxin Level

Endotoxin level is <0.1 EU/µg (<0.01ng/µg) protein as determined by the LAL method.

Concentration

10 and 25 µg sizes are bottled at 200 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.

Storage & Handling

Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.

Activity

ED₅₀ = 0.2 - 1.0 ng/ml, corresponding to a specific activity of 1.0 - 5.0 x10⁶ units/mg, as determined by the dose dependent stimulation of CTLL2 cell proliferation.

The specific activity of recombinant mouse IL-2 is approximately 9.07 x 10⁴ IU/µg when compared against the Non WHO Reference Material for Murine Interleukin-2 (NIBSC code: 93/566) as determined by the dose dependent stimulation of CTLL2 cell proliferation.

ED₅₀ = 0.4 - 2.0 ng/ml, corresponding to a specific activity of 0.5 - 2.5 x10⁶ units/mg, as determined by the dose dependent stimulation of HT-2 cell proliferation.

For more information on specific activity, please visit the Recombinant Protein Unit Conversions page.

Application

Bioassay

Application Notes

BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are verified in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at tech@biolegend.com.

Additional Product Notes

Get a 50% discount on this product when purchased in our Activation Bundles. Restrictions apply. Learn more…

Application References

(PubMed link indicates BioLegend citation)

1. Detanico T, et al. 2011.J. Immunol. 187:82. PubMed
2. Malu DT, et al. 2011. J. Immunol. 186:6271. PubMed
3. Alcaide P, et al. 2012. J. Immunol. 188:1421. PubMed
4. Williams JW, et al. 2013. Am J Physiol Lung Cell Mol Physiol. 305:693. PubMed

Product Citations

1. Vella JL, et al. 2021. Life Sci Alliance. 4:. PubMed
2. Zhang Y, et al. 2022. Nat Med. 28:1421. PubMed
3. Jou E, et al. 2022. Sci Immunol. 7:eabn0175. PubMed
4. Balood M, et al. 2022. Nature. 611:405. PubMed
5. Benakis C, et al. 2022. Elife. 11: . PubMed
6. An HW, et al. 2022. Cell Rep. 41:111878. PubMed
7. Chan L, et al. 2022. Cells. 12: . PubMed
8. Liu Z, et al. 2023. Breast Cancer Res. 25:10. PubMed
9. Yang J, et al. 2021. Cancer Immunol Res. 9:200. PubMed
10. Han S, et al. 2022. Cancer Immunol Res. 10:437. PubMed
11. Ye L, et al. 2022. Cell Metab. 34:595. PubMed
12. Kania AK, et al. 2022. J Immunol. 208:1873. PubMed
13. Wu MJ, et al. 2022. Cancer Discov. 12:812. PubMed
14. Aso K, et al. 2023. Nat Commun. 14:984. PubMed
15. Liu HJ, et al. 2023. Nat Commun. 14:1214. PubMed
16. Palakurthi B, et al. 2023. Nat Commun. 14:2109. PubMed
17. Vereertbrugghen A, et al. 2023. J Neuroinflammation. 20:120. PubMed
18. Adu-Berchie K, et al. 2023. Nat Commun. 14:3546. PubMed
19. Li Q, et al. 2022. Cell Rep. 40:111308. PubMed
20. Ruscetti M, et al. 2020. Cell. 181:424. PubMed
21. Liu B, et al. 2019. Nat Commun. 10:354. PubMed
22. Zhou Z, et al. 2021. Nat Biomed Eng. 5:1320. PubMed
23. Wabitsch S, et al. 2021. STAR Protoc. 2:100517. PubMed
24. Sultan H, et al. 2018. Cancer Immunol Res. 6:617. PubMed
25. Shi S, et al. 2020. Clin Cancer Res. 26:5990. PubMed
26. Guo Z, et al. 2016. Nat Commun. 7:10307. PubMed
27. Gomez–Lopez N, et al. 2019. J Immunol. 203:1793. PubMed
28. Montes de Oca M, et al. 2020. PLoS Pathog. 16:e1008994. PubMed
29. Jacobsen JT, et al. 2021. Science. 373:. PubMed
30. Cha SE, et al. 2021. Oncoimmunology. 10:1899469. PubMed
31. Hurrell BP, et al. 2019. Cell Rep. 29:4509. PubMed
32. Hrdinka M, et al. 2016. PLoS One. 11: 0162863. PubMed
33. Walter F, et al. 2020. PLoS One. 15:e0239369. PubMed
34. Takushi SE, et al. 2020. Hum Gene Ther. 31:626. PubMed
35. Morales-Mantilla DE, et al. 2022. Elife. 11:. PubMed
36. Chen X, et al. 2021. Cell Rep. 37:109991. PubMed
37. Kania AK, et al. 2021. Immunohorizons. 5:918. PubMed
38. Palazon A, et al. 2017. Cancer Cell. . 10.1016/j.ccell.2017.10.003. PubMed
39. Jacque E, et al. 2015. J Exp Med. 212:883. PubMed
40. Swan G, et al. 2021. Front Immunol. 12:641188. PubMed
41. Hills LB, et al. 2021. J Immunol. 206:89. PubMed
42. Han S, et al. 2020. Oncoimmunology. 9:1737368. PubMed
43. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
44. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
45. Muthalagu N, et al. 2020. Cancer Discov. 1.022222222. PubMed
46. Pasciuto E, et al. 2020. Cell. 182:625. PubMed
47. Zeis P, et al. 2020. Immunity. 53:775. PubMed
48. Loo CS, et al. 2020. Immunity. 53:143. PubMed
49. Minns D, et al. 2021. Nat Commun. 12:1285. PubMed
50. Xu H, et al. 2021. J Clin Invest. 131:. PubMed
51. Jiang P, et al. 2018. Nat Med. 24:1550. PubMed
52. Mohammadpour H, et al. 2020. JCI Insight. 5:00. PubMed
53. Roberts KJ, et al. 2021. Sci Rep. 11:19422. PubMed
54. Zhou S, et al. 2021. Adv Funct Mater. 31:. PubMed
55. Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed
56. Knox T, et al. 2019. Sci Rep. 9:6136. PubMed
57. Detanico T, et al. 2011. J Immunol. 187:82. PubMed
58. Bao K, et al. 2016. J Immunol. 197(11):4371-4381. PubMed
59. Yue T, et al. 2022. Cell Death Differ. 29:218. PubMed
60. Walker JA, et al. 2020. Immunity. 51(1):104-118. PubMed
61. Frech M, et al. 2020. MethodsX. 7:101054. PubMed
62. Choi HS, et al. 2020. Cell Rep. 30:2989. PubMed
63. Patterson DG, et al. 2021. J Immunol. 207:1798. PubMed

Antigen Details

Structure

Cytokine

Bioactivity

Proliferation of T lymphocytes, B cells, anti-inflammatory, hematopoiesis, tumor surveillance

Cell Sources

T cells

Cell Targets

T cells, B cells, NK cells, LAK cells, monocytes, macrophages, oligodendrocytes

Receptors

High affinity heterotrimer of IL-2Rα/β/γ, intermediate affinity homodimer IL-2Rα (CD25; p55; Tac) and heterodimer IL-2Rβ (CD122)/γ; γ-subunit (CD132) in common with IL-4R, IL-7R, IL-13R, IL-15R

Cell Type

Embryonic Stem Cells, Hematopoietic stem and progenitors

Biology Area

Cell Biology, Stem Cells

Molecular Family

Cytokines/Chemokines

Regulation

Upregulated by NFAT; downregulated by TCF-8, CIF (colostrum inhibitory factor)

Gene ID

16183 View all products for this Gene ID

UniProt

View information about IL-2 on UniProt.org

Documentation

• Technical Data Sheet (pdf)
• Certificate of Analysis
• Safety Data Sheet

Reviews

Related Pages & Pathways

Related FAQs

Why choose BioLegend recombinant proteins?

     • Each lot of product is quality-tested for bioactivity as indicated on the data sheet.
     • Greater than 95% Purity or higher, tested on every lot of product.
     • 100% Satisfaction Guarantee for quality performance, stability, and consistency.
     • Ready-to-use liquid format saves time and reduces challenges associated with reconstitution.
     • Bulk and customization available. Contact us.
     • Learn more about our Recombinant Proteins.

How does the activity of your recombinant proteins compare to competitors?

We quality control each and every lot of recombinant protein. Not only do we check its bioactivity, but we also compare it against other commercially available recombinant proteins. We make sure each recombinant protein’s activity is at least as good as or better than the competition’s. In order to provide you with the best possible product, we ensure that our testing process is rigorous and thorough. If you’re curious and eager to make the switch to BioLegend recombinants, contact your sales representative today!

What is the specific activity or ED50 of my recombinant protein?

The specific activity range of the protein is indicated on the product datasheets. Because the exact activity values on a per unit basis can largely fluctuate depending on a number of factors, including the nature of the assay, cell density, age of cells/passage number, culture media used, and end user technique, the specific activity is best defined as a range and we guarantee the specific activity of all our lots will be within the range indicated on the datasheet. Please note this only applies to recombinants labeled for use in bioassays. ELISA standard recombinant proteins are not recommended for bioassay usage as they are not tested for these applications.

Have your recombinants been tested for stability?

Our testing shows that the recombinant proteins are able to withstand room temperature for a week without losing activity. In addition the recombinant proteins were also found to withstand four cycles of freeze and thaw without losing activity.

Does specific activity of a recombinant protein vary between lots?

Specific activity will vary for each lot and for the type of experiment that is done to validate it, but all passed lots will have activity within the established ED50 range for the product and we guarantee that our products will have lot-to-lot consistency. Please conduct an experiment-specific validation to find the optimal ED50 for your system.

How do you convert activity as an ED50 in ng/ml to a specific activity in Units/mg?

Use formula Specific activity (Units/mg) = 10^6/ ED50 (ng/mL)

Certificate of Analysis